Avycaz, Zavicefta (avibactam) is a small molecule pharmaceutical. Avibactam was first approved as Avycaz on 2015-02-25. It is used to treat escherichia coli infections, intraabdominal infections, klebsiella infections, proteus infections, and pseudomonas infections in the USA. It has been approved in Europe to treat bacterial pneumonia, gram-negative bacterial infections, pneumonia, soft tissue infections, and urinary tract infections. Avycaz's patents are valid until 2032-06-15 (FDA).
|Indication||bacterial pneumonia, escherichia coli infections, gram-negative bacterial infections, intraabdominal infections, klebsiella infections, pneumonia, proteus infections, pseudomonas infections, soft tissue infections, urinary tract infections|
|Drug Class||Beta-lactamase inhibitors|